Stay updated on our latest news and events.
Due to the changes in technology in the inhalation space, the pharmaceutical industry is going to start to see some changes.
Our very own Director of Inhalation Science and Product Development at Recipharm, Lei Mao, spoke with Manufacturing Chemist about the current innovations in the inhaled drugs market.
As a result of the worldwide fight against COVID-19, we have been experiencing higher demand for our goods and services, particularly when it comes to the manufacture of antibiotics. With this, we have had to adapt and make changes to our supply chain processes to alleviate the strain on day-to-day operations.
In light of the current situation, there is a global concern across the pharmaceutical industry around what the COVID-19 pandemic means for the global supply chain, the current pharma M&A activity taking place in the market and ultimately how CDMOs will be impacted in the long-term.
Although reports suggest that Europe may be overcoming the peak in coronavirus cases and things are starting to look up for many countries, our Recipharm teams are continuing to support their local communities in every way they can.
What is myeloma?
Gathering information and knowledge around the specific patient population and other market conditions, combined with an understanding of stability issues, will allow for a clear development strategy to be outlined and implemented.
Today, demand is for more flexible solid manufacturing capacity… The challenge lies in being able to adapt current operations to offer more flexible manufacturing operations.
We are delighted to have been awarded with Life Science Leader's CMO Leadership Award once again.
Recipharm’s reputation is built on using our expertise and capabilities to support pharmaceutical companies in taking their products from early development through to commercial manufacturing. Of course, it is our desire to bring life-saving medicines to patients that ultimately drives us.